Inhibition of the PD-1/PD-L1 pathway activates cytotoxic T cells that trigger anti-tumor activity and induce morbilliform that is known as a type IV hypersensitivity reaction [37,163,180,181]. Here, PDCD1 is linked to neoplasm.